Topas already has three important collaborations in place and is actively pursuing additional partnerships.
Boehringer Ingelheim: In 2018, Topas signed a multi-year agreement with Boehringer Ingelheim to collaborate in the field of antigen-specific tolerance induction to tackle anti-drug antibodies. The initial focus of the collaboration is on virus-based delivery vectors that confer novel therapeutics to patients. Under the terms of the agreement, Topas is responsible for the design, application and production of its proprietary tolerizing particles while Boehringer Ingelheim is contributing its antigen know-how and its pharmacology expertise to the collaboration in order to develop tolerance-generating adjuvant candidates. Boehringer Ingelheim has an option to license several pre-clinical development candidates produced under the collaboration for development and commercialization.
Eli Lilly and Company: In 2017, Topas signed a multi-year agreement with Eli Lilly and Company (Lilly) to collaborate in the field of antigen-specific tolerance induction with an initial focus on external antigens thought to induce inflammation and/or autoimmune disease. Topas is responsible for conducting pre-clinical proof-of-principle studies in collaboration with Lilly to generate drug candidates. Under the terms of the agreement, Lilly has an option for all candidates produced under the collaboration for in-licensing and further development. Topas receives R&D funding and will participate in the future success of any compounds in-licensed by Lilly.
Evotec: Topas also has had ongoing since the end of 2016 a co-development program with Evotec to treat Type 1 diabetes, which is currently in proof-of-concept pre-clinical studies.